ED
PRVL

Exane Derivatives’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Exane Derivatives’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change % 		Capital Flow Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,700
Closed -$37.7K – 857
2020
Q3 		$37.7K Buy
+3,700
New +$37.7K 0.01% 370